Results 61 to 70 of about 499,883 (421)

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis

Cells, 2020
Ulcerative colitis is a chronic inflammatory disease confined to the colon. Although the etiopathogenesis remains unknown, small bowel dysfunctions like histological and permeability alterations have been described in ulcerative colitis. We evaluated the
Ho-Su Lee, Maaike Vancamelbeke, Sare Verstockt, Tom Wilms, Bram Verstockt, João Sabino, Marc Ferrante, Séverine Vermeire, Isabelle Cleynen   +8 more
doaj   +1 more source

Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression

Journal of Innate Immunity, 2021
Background and Aims: Inflammatory mediator S100A9 is dramatically elevated in ulcerative colitis and correlates with disease severity. S100A9 is a potential molecule to target for the treatment of colitis, but to date, there is no effective targeting ...
Zhengshuo Li, Xiaoyue Zhang, Can Liu, Qiu Peng, Yangge Wu, Yuqing Wen, Run Zheng, Qun Yan, Jian Ma   +8 more
doaj   +1 more source

Ulcerative Colitis

Southern Medical Journal, 1961
John Van Prohaska, Lester R. Dragstedt, Richard G. Thompson   +2 more
openaire   +4 more sources

Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: Pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll"? [PDF]

, 2006
The pathogenesis of inflammatory bowel disease (IBD) is only partially understood. Various environmental and host (e.g. genetic-, epithelial-, immune and non-immune) factors are involved.
Fischer, Simon, Gál, István, Lakatos, László, Lakatos, Péter László, Papp, János   +4 more
core   +1 more source

The atypical KRASQ22K mutation directs TGF‐β response towards partial epithelial‐to‐mesenchymal transition in patient‐derived colorectal cancer tumoroids

Molecular Oncology, EarlyView.
TGF‐β has a complex role in cancer, exhibiting both tumor‐suppressive and tumor‐promoting properties. Using a series of differentiated tumoroids, derived from different stages and mutational background of colorectal cancer patients, we replicate this duality of TGF‐β in vitro. Notably, the atypical but highly aggressive KRASQ22K mutation rendered early‐
Theresia Mair, Philip König, Milena Mijović, Jessica Kalla, Anil Baskan, Loan Tran, Kristina Draganić, Pedro Morata Saldaña, Carlos Uziel Pérez Malla, Janette Pfneissl, Andreas Tiefenbacher, Julijan Kabiljo, Velina S. Atanasova, Lisa Wozelka‐Oltjan, Leonhard Müllauer, Michael Bergmann, Raheleh Sheibani‐Tezerji, Gerda Egger   +17 more
wiley   +1 more source

New Diagnostic Possibilities for Determining the Activity of Ulcerative Colitis: The Role of Neutrophils

Архивъ внутренней медицины, 2022
The incidence of ulcerative colitis has been increasing in recent years, and its manifestation at a young age has become a trend that is prognostically unfavorable.
E. V. Bolotova, K. A. Yumukyan, A. V. Dudnikova   +2 more
doaj   +1 more source

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.

Gastroenterology, 2015
BACKGROUND & AIMS Ulcerative colitis (UC) is difficult to treat, and standard therapy does not always induce remission. Fecal microbiota transplantation (FMT) is an alternative approach that induced remission in small series of patients with active UC ...
P. Moayyedi, M. Surette, P. Kim, J. Libertucci, M. Wolfe, Catherine Onischi, D. Armstrong, J. Marshall, Z. Kassam, W. Reinisch, Christine H. Lee   +10 more
semanticscholar   +1 more source

Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis [PDF]

, 1990
Between February 26, 1981, and July 30, 1987, 36 patients underwent orthotopic liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis.
Higashi, H, Kakizoe, S, Marsh, JW, Starzi, TE, Tzakis, A, Yanaga, K   +5 more
core   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

New England Journal of Medicine, 2017
To the Editor: Sandborn et al. (May 4 issue)1 raise two important issues that deserve attention. First, when patients with moderate-to-severe ulcerative colitis show no improvement in response to treatment with mesalamine or a dosage of glucocorticoids ...
W. Sandborn, C. Su, B. Sands, G. D'Haens, S. Vermeire, S. Schreiber, S. Danese, B. Feagan, W. Reinisch, W. Niezychowski, G. Friedman, N. Lawendy, Dahong Yu, D. Woodworth, A. Mukherjee, Haiying Zhang, P. Healey, J. Panés   +17 more
semanticscholar   +2 more sources